A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 14673 participants.
Also called NCT02019264
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 14,673 participants
- Sponsor
- Registry
-
NCT02019264 -
2013-000324-34
-
- Other papers using this trial's data
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Chile, Mexico, New Zealand, Poland, Bahamas
- Registry status
- Completed
Technical summary
Registry record NCT02019264. Randomized; double masking; primary purpose treatment. Start 2014-01-24 (actual); primary completion 2018-05-14 (actual). Results posted on 2019-07-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
- Acronym
- CAMELLIA-TIMI
- Condition
- Cardiovascular Disease
- Condition
- High Cardiovascular Risk
- Condition
- Obesity
- Condition
- Overweight
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Lorcaserin hydrochloride
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eisai Inc.
- Collaborator
- The TIMI Study Group
Record details
- Record id
cardio:ct-nct02019264- Content hash
d374e2a1972ac50f454eff27bc9c196e5d3121ca614ad51bc5aebb1eca6b9643